Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Millennium’s Velcade shows promise in lymphoma studies
The findings were from an ongoing phase II National Cancer Institute-sponsored study and final results from a phase II investigator initiated study examining the potential role of Velcade
The findings were from an ongoing phase II National Cancer Institute-sponsored study and final results from a phase II investigator initiated study examining the potential role of Velcade
Both companies will now share US development costs and future net profits, if any, derived from sales in the US of a resultant therapeutic product candidate for the
Results from an earlier 28 day European trial of FM-VP4 suggest that LDL cholesterol, or “bad” cholesterol, levels may continue to decrease when FM-VP4 is given to patients
The company’s investigational new drug application filing was announced on January 4, for a phase I clinical trial of a proprietary neural cell therapy product, HuCNS, in Batten
PXD101 is a small molecule histone deacetylase (HDAC) inhibitor being evaluated in advanced multiple myeloma. The companies reported that initiation of this phase II trial triggered an undisclosed
The compounds are PI3K inhibitors that were created under a joint drug discovery program. As part of the transduction signaling technology, these novel compounds could lead to new
Scios Inc, another Johnson & Johnson company, currently markets the product on behalf of Centocor. ESP Pharma has now acquired distribution, manufacturing, development and marketing rights, all relevant
These findings may offer new treatment options for Huntington’s disease, which currently has no cure. Huntington’s disease is a neurological disorder caused by a mutation in the gene
RhASB (galsulfase) is BioMarin’s investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI), also known as Maroteaux-Lamy Syndrome, an inherited debilitating, life-threatening disease which affects
The company’s small molecule, melanocortin receptor subtype-4 (MC4) selective agonist was shown to reduce food intake and body weight and improve metabolic parameters in rodent models of obesity.